Jean-Jacques Kiladjian/LinkedIn
Dec 8, 2025, 14:46
Jean Jacques Kiladjian Presents 1st Results of the ROP-ET Study at ASH25
Jean Jacques Kiladjian, Head of Clinical Research Department of Inserm, shared on LinkedIn:
”Proud to have presented at American Society of Hematology ASH25 , on behalf of my co-investigators from 10 European countries, the first results of the ROP-ET study showing that ropeginterferon-alpha 2b is also an effective and safe treatment for patients with essential thrombocythemia ET who have no other therapeutic option.
At 12 months: 65% of durable (>3 months) complete hematologic response, no disease progression, only 1.5% of major thrombotic events, symptoms improvement in 62% of patients.”
Stay updated with Hemostasis Today.
-
Dec 8, 2025, 15:09Paul Bolaji Invites You to Nigerian Stroke Leaders’ Summit 2025
-
Dec 8, 2025, 14:58Mohammad E Barbati on ClotTriever System for Postpartum Iliofemoral DVT
-
Dec 8, 2025, 11:23Jorge Di Paola and Diane Krause Take Their Awards at ASH25
-
Dec 8, 2025, 11:08Andreas Tiede: This Will Change Hematology Forever
-
Dec 8, 2025, 09:39Asfand Yar Cheema Honored with Abstract Achievement Awards at ASH25
-
Dec 8, 2025, 09:27Ana Rita Rodrigues on the Impact of Post-Stroke Dysphagia
-
Dec 8, 2025, 09:19Sanam Loghavi and Shannon McWeeney at Joint Session on AI nad Hematology at ASH25
-
Dec 7, 2025, 18:43ASH25 Day 2: Don’t Miss The Highlights
-
Dec 7, 2025, 18:05Heghine Khachatryan Highlights a Patient-Friendly Breakthrough: Finger-Prick Micro-Sampling for Platelet Function